

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Jabbour et al.)	
Serial No:	10/511,480)	Examiner:
Cnfrm. No.:	6559)	J.D. Anderson
Filed:	April 10, 2003)	Art Unit:
For :	FP RECEPTOR ANTAGONISTS OR PGF2 ALPHA ANTAGONISTS FOR TREATING PATHOLOGICAL CONDITIONS OF THE UTERUS)	1614

STATEMENT IN ACCORDANCE WITH 37 C.F.R. § 1.821

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. § 1.821, applicants hereby submit a revised Sequence Listing via EFS-Web and confirm that the Sequence Listing contains no new matter. A representative of the Electronic Business Center of the U.S. Patent and Trademark Office confirmed that when submitting the Sequence Listing via EFS-Web as a text file (i.e., a .txt file), applicants are not required to *additionally* file a “paper” copy of the Sequence Listing, and that applicants are not required to submit a statement confirming that the paper copy and computer readable form of the Sequence Listing are identical (i.e., because no paper copy is being filed).

Respectfully submitted,

Dated: April 9, 2007

/Edwin V. Merkel/
Edwin V. Merkel
Registration No. 40,087

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1128
Facsimile: (585) 263-1600